Therapeutic interventions that target VEGF receptor 2 (VEGFR2) and integrins have been evaluated as anti-angiogenic treatments, in accordance with their key roles in the pathogenesis of tumour angiogenesis [2, 3]. Here, KDR is linked to neoplasm.